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Introduction
Significant advancements have been made in the last 
30 years in the diagnosis of upper tract urothelial carcinoma 
(UTUC), but certain aspects still remain a challenge for the 
clinician. Computerized tomographic urography (CTU) 
has made great strides in aiding the diagnosis of urothelial 
malignancies with 88–100% sensitivity and 93–100% 
specificity on meta-analysis (1). Additionally, it can detect 
filling defects as small as 5 mm (2). A major barrier is that 
imaging alone fails to provide tissue diagnosis to guide 
further treatment. It therefore remains part of the work-
up, rather than a means for definitive diagnosis. Repeated 
radiation exposure also remains a concern (1).
Currently, ureteroscopy with biopsy is the cornerstone 
of initial diagnosis and ongoing surveillance (3,4). Using 
our method of diagnosis and specimen handling, we have 
achieved a 97.2% success rate in grading biopsy specimens, 
mainly by changing the way we process specimens (5). 
Despite this, ureteroscopy also has its limitations, which 
will be described herein.
All of the above highlight the need for the development 
of a non-invasive means for diagnosis. The role of urinary 
biomarkers has been an interest of study as a method to 
aid diagnosis and surveillance after treatment without 
need for radiation or ureteroscopy and general anesthesia. 
Cytology is the most widely utilized. Improved diagnostic 
correlation has recently been suggested with introduction 
of the Paris System for urine cytology (6,7). Other options, 
such as FISH have been discussed previously. Currently the 
detection of DNA mutations and methylation markers in 
voided urine has gained some popularity in the literature, 
and preliminary analysis shows promise as a biomarker in 
the detection of UTUC. 
Methods
A literature review was performed by searching PubMed 
and Google Scholar using relevant keywords. Results were 
screened for pertinent publications, with a focus placed 
on publications from the last 10 years. Further references 
were obtained from the citations of these papers, as well as 
guidelines and textbooks.
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Ureteroscopic biopsy
We have reported notable success with ureteroscopic 
biopsy as described above, and other studies have reported 
similar success with a sensitivity and specificity of 83% and 
100% respectively (8). Arguments have been made for the 
avoidance of ureteroscopy and biopsy in cases of positive 
urine cytology and an obvious lesion on CTU when the 
added diagnostic benefit will not affect management (9). 
However, in many cases, the outcome of ureteroscopy and 
biopsy will direct potential neoadjuvant chemotherapy or 
nephron-sparing treatments and is therefore beneficial. 
Below we describe our method of ureteroscopic biopsy 
(10,11).
Initial approach and surveillance
Evaluation for upper tract urothelial cancer should always 
begin with thorough cystoscopy of the bladder to rule 
out concomitant bladder tumors. Urine cytology from 
the bladder is then obtained and bilateral retrograde 
pyelograms are performed with great care to avoid excessive 
back pressure and extravasation. Retrograde pyelogram 
sets the stage for what to expect. The index of suspicion for 
encountering an upper tract lesion will be high if a filling 
defect or stricture is demonstrated.
Ureteroscopic examination of the affected side 
commences with “no touch” technique. Via this method, 
manipulation of the urothelium is minimized as not to 
induce mucosal trauma or bleeding, which could impair 
detection of subtle lesions. Traditionally, a small semi-rigid 
ureteroscope is used to examine the distal ureter under 
direct vision. No wire is passed prior to ureteroscopy and 
the ureteral orifice is ideally entered without the use of 
dilation. The ureteroscope is then passed as proximally 
as possible and replaced with a guidewire, which is not 
advanced beyond the proximal extent of ureteroscopic 
examination. The smallest flexible ureteroscope available 
is then passed over the wire to this point. The remainder 
of the ureter is examined, and complete ureterorenoscopy 
is performed in a systematic manner from the upper pole 
to lower pole, to ensure direct examination of all the 
potential space of the intraluminal collecting system. If 
ureteral tumors are encountered during initial ureteroscopy, 
these are biopsied and treated at the time of discovery. 
Performance of upper urinary tract surveillance with the 
exclusive use of flexible ureteroscopy is now possible with 
the development of optimal distal shaft durometer (shaft 
stiffness), making semi-rigid instruments necessary in only 
about half of all cases (12).
Biopsy technique
When a lesion is encountered, cytology washings are taken 
via the irrigation channel of the ureteroscope. Then biopsy 
can be performed using a variety of methods, including 3-F 
cold cup forceps (Piranha), 6-F back loading biopsy forceps 
(BIGopsy), or ureteroscopic basket. Several studies have 
compared these options and noted a 74.9–79% diagnostic 
rate for 3-F cold cup forceps, 81.9–90% for BIGopsy and 
87–100% when using a 2.2-F or 2.4-F wire basket (13,14). 
In our practice, we favor 3-F cold cup forceps or a 2.4-F 
stainless steel FlatWire basket (Figure 1). We find BIGopsy 
forceps impractical due to its back loading nature, tendency 
to obscure the field of view, and its severe limitations on 
ureteroscopic deflection (15). Our choice of cold cup 
forceps versus basket depends on the nature of the lesion; 
with the cold cup biopsy forceps being superior for sessile 
lesions, while the stainless steel basket is useful for large 
friable tumors. We have found that when suitable, the 
FlatWire basket obtains superior diagnostic results (16). 
Relatively large volumes of tumor can be sampled (Figure 2). 
It is the opinion of the authors that stainless steel FlatWire 
baskets are superior to nitinol baskets for luminal tissue 
biopsy. Relative to the round, soft wires which comprise 
nitinol baskets, the flat wires of the stainless steel basket 
are more rigid and superior in grasping and holding tissue 
in the angle between the wires with flat edges, allowing for 
better tissue sampling.
Once the biopsy is obtained, the tumor sample, biopsy 
device and ureteroscope are removed together as one unit, 
in order to avoid shearing and loss of the sample. Following 
this, aspiration for cytology is repeated. If the lesion is 
endoscopically treated, a final cytology is taken following 
treatment.
Specimen processing
All specimens in our practice are sent to cytopathology and 
processed using the Cytospin technique (10). Any viable 
tissue is prepared using a cell block. We developed this 
method as we found that ureteroscopy specimens processed 
as traditional histological specimens were destroyed during 
processing. By sending these tumor samples as cytology, 
diagnostic yield improved from 42.9% to 97.2% (5). 
Similarly, when Vashistha et al. examined the accuracy of 
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ureteroscopy biopsy in 118 samples, specificity was 100% 
and sensitivity was 83.0% (8). Specimen processing was 
not overtly addressed, however it was implied that biopsies 
underwent traditional histological preparation.
Limitations
Despite these successes, ureteroscopic biopsy still remains 
an imperfect technique in that staging is notoriously 
inaccurate. Despite the aforementioned specificity and 
sensitivity, Vashistha found disappointing stage concordance 
between biopsy specimen and final pathology of 58.6% (8). 
Therefore, tumor grade remains the guiding force in 
treatment decisions (3,4). 
Given these limitations, efforts have been made to 
identify patients at risk for muscle invasive disease. 
Margolin et al. found that patients with clinical high grade 
tumors on ureteroscopic biopsy were found to have a 60% 
positive predictive value (PPV) for muscle invasion. If 
subepithelial tissue was captured on biopsy and was positive, 
this increased the PPV to 86% (17). 
Other avenues of diagnosis have been explored, such 
as percutaneous biopsy. In a study looking at 26 patients 
who underwent percutaneous biopsy for a variety of 
indications (nondiagnostic URS, prior cystectomy or 
poor surgical candidate), successful diagnosis of urothelial 
carcinoma was made in 85% of cases. However similar to 
ureteroscopic biopsy, the ability for staging remains limited. 
In the same study, 14/24 patients had grade information 
available and 86% demonstrated concordance with final 
pathology. Despite diagnostic rates that are comparable to 
URS and biopsy, percutaneous access comes with the risk 
of tumor seeding. In the aforementioned study, 13% of 
patients demonstrated local recurrence. However, this was 
determined as unrelated to biopsy as the tumor recurrence 
was outside of the needle tract. There is, however, literature 
that supports the risk of tumor seeding, predominantly with 
percutaneous resection and laparoscopic intervention (18). 
Urinary biomarkers
The use of urinary biomarkers is an invaluable adjunct to 
diagnosis, with cytology being the most popular, despite its 
flaws. Cytology does not always provide a clear diagnostic 
picture, and often times ureteroscopy is needed to further 
characterize a lesion prior to intervention, which results 
in several issues. Firstly, not only is ureteroscopy often 
needed for initial diagnosis, but if a lesion is found, it 
may subject patients to a need for repeated ureteroscopic 
surveillance. This results in increased fluoroscopic 
exposure as well as repeated general anesthesia. Secondly, 
data has remained mixed on whether diagnostic URS 
increases the risk of intravesical recurrence of urothelial 
carcinoma (19,20). A meta-analysis by Guo et al., which 
looked at 8 studies including 3975 patients, found that 
those who undergo diagnostic URS are at higher risk of 
intravesical recurrence however this did not negatively 
impact survival parameters (21). The field of biomarker 
development for diagnosis and monitoring therefore 
remains a continued area of interest.
Figure 1 Instruments for ureteroscopic biopsy of upper tract 
urothelial carcinoma: 3-F cup biopsy forceps (left) and 2.4-F 
stainless steel flatwire basket.
Figure 2 Relatively large luminal tissue samples can be obtained 
with good endoscopic visualization and preservation of flexible 
ureteroscope deflection using the 2.4-F stainless steel FlatWire 
basket. Note the tumor tissue caught in the notch between the flat 
wires.
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Cytology
Although cytology remains a gold standard diagnostic tool 
for UTUC, voided cytology is notoriously inaccurate, with 
false negative rates of 50–89% (22,23). Selective cytology 
has demonstrated greater diagnostic accuracy with meta-
analysis revealing a 53.1% sensitivity with 90% specificity 
based on biopsy. Sensitivity is highest for high grade at 
70% but notably lower for low grade (46%). Part of this 
ambiguity arises from the great variability in how cellular 
“atypia” is characterized and the notoriously poor inter-and 
intraobserver agreement in grading urine cytology (22,24). 
To solve the latter problem, new methods of cytologic 
grading have been developed. The “Paris System” was first 
described in the literature in 2016 as a new classification 
method that uses specific criteria in an effort to increase 
diagnostic accuracy and focuses mainly on high grade 
diagnosis (24). Table 1 describes the different categories 
set forth by this system. Studies have shown a 71–78.6% 
sensitivity and 86–100% specificity rate and an almost 
double rate of surgical concordance when compared with 
traditional cytology in upper tract disease (63% compared 
to 34%) (6,7,25). The false negative rate was reported 
as 7% and attributed to sampling errors, compared to 
historical rates of 26% (6). McIntire et al. also found that 
implementing the Paris System decreased equivocal or 
atypical diagnoses by 55%. However, Xing et al., as well 
as Simon et al., reported a decrease in sensitivity when 
compared to traditional cytology (7,25,26). Therefore, 
controversy still remains, as does the ongoing issue of 
detecting low grade disease. 
Fluorescence in situ hybridization testing (FISH)
FISH testing uses fluorescent probes to detect abnormalities 
in chromosomes 3, 7, 17 and 9p21 (27). While popular as an 
adjunct to bladder cancer diagnosis, efforts have been made 
to apply FISH to UTUC with inconsistent results. When 
applied to voided urine without concomitant bladder tumor, 
sensitivity and specificity has varied widely, and reported at 
54–76.7% and 78–94.7% respectively (28,29).
DNA methylation biomarkers
The role of epigenetic changes in cancer has been 
increasingly recognized. Based off tissue immunology, 
the methylation status of multiple genes has been shown 
to be associated with UTUC and this work has been 
extrapolated to the development of urinary biomarkers. 
Two studies looked at the diagnosis of UTUC by examining 
voided samples for GDF15, TMEFF2 and VIM promoter 
methylation status. Monteiro-Reis et al. looked at 22 
patients with known UTUC and found that this panel 
detected UTUC with 91% sensitivity. UTUC samples 
demonstrated a significantly higher degree of methylation 
and this was used to calibrate levels to controls, resulting 
in a specificity of 100%. Furthermore, VIM methylation 
status independently was associated with stage and low 
VIM methylation levels were associated with poor disease-
specific survival. It should be noted that only 3 patients had 
low grade UTUC and no analysis was performed to look 
at accuracy of diagnosis in these samples (30). Similarly, 
Guo et al examined a similar panel, with the addition of 
genes CDH1, HSPA2 and RASSF1A with a notably lower 
sensitivity of 82% and specificity of 68%. Neither of these 
studies examined whether methylation could distinguish 
between lower and upper tract lesions (31).
Gene mutation biomarkers
Several gene mutations have been associated with urothelial 
carcinoma, and efforts have been made to identify urinary 
assays that would identify these abnormalities. Hotspot 
mutations in telomerase reverse transcriptase (TERT) 
have been investigated as a possible target as well as 
FGFR3. When examining TERT and FGFR3 mutations in 
conjunction with cytology had a sensitivity of 78.6% and 
specificity of 96% (32). 
Miscellaneous
Other tumor markers have been described for upper tract 
Table 1 Diagnostic categories described by the Paris system
Nondiagnostic/unsatisfactory 
Negative for high-grade urothelial carcinoma (NHGUC) 
Atypical urothelial cells (AUC) 
Suspicious for high-grade urothelial carcinoma (SHGUC) 
High-grade urothelial carcinoma (HGUC) 
Low-grade urothelial neoplasm (LGUN) 
Other: primary and secondary malignancies and 
miscellaneous lesions
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detection over the past 20 years such as the BTA stat 
test, FDP test, nuclear matrix protein 22 (NMP 22), and 
ImmunoCyt (11). Despite sometimes promising results, 
they have failed to achieve mainstream or guideline 
endorsed use.
Conclusions
Ureteroscopy with biopsy in conjunction with urinary 
markers has greatly increased our ability to detect and 
diagnose UTUC, however barriers remain. Great strides 
have been made with the improvement in endoscopic 
techniques for UTUC diagnosis and specimen handling 
which have improved diagnostic accuracy. There is an 
ongoing challenge in the use of urinary cytology, but 
with improvements and standardization in specimen 
interpretation, this may improve. Similarly, the role of 
DNA markers in the role of diagnosis remains experimental 
but holds promise to increase future diagnostic capabilities 
in UTUC. Further large volume and prospective studies are 
still needed in order to determine the best means of non-
invasive UTUC diagnosis.
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